DE-LYCRA
15.7.2021 14:47:04 CEST | Business Wire | Press release
Textile technology innovation leaders, The LYCRA Company and HeiQ , have entered into a broad-based collaboration across multiple technology and brand platforms that promises to bring more innovative, quality-enhancing and sustainable textile technologies to consumers around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005642/en/
Building on exploratory discussions that started in early 2019, HeiQ and The LYCRA Company have elected to leverage their shared philosophies and strengths in textile science, commercial networks, and global marketing to drive innovation platforms into broad textile markets. The companies envision consumer-branded innovations in the stretch, thermoregulation, freshness and sustainability market spaces.
“We are pleased to announce the launch of this collaboration, the culmination of conversations that began two years ago,” commented Steve Stewart, chief brand and innovation officer at The LYCRA Company. “By combining the strength of both companies, we will continue to drive meaningful innovation within the textile industry, delivering new solutions at a quicker pace to a broader audience.”
Together, The LYCRA Company and HeiQ bring trusted expertise across the global textile value-chain of yarn processors, fabric mills, garment producers, brands and retailers and demonstrate a commitment to sustainable, consumer-driven innovations, delivered through partnerships, that take textile performance to unprecedented levels. These industry leaders have complementary strengths: whereas The LYCRA Company is the consumer-recognized leader in branded fibers and fabrics addressing needs for sustainable stretch, warming and cooling, HeiQ is a renowned innovator in finished-based innovations addressing freshness, sustainability, smart temperature management, antiviral, dryness, and many other market spaces.
The initial and first of many innovation platforms will roll out through the summer, bringing a new dimension of comfort and confidence to the consumer by delivering HeiQ freshness and antiviral benefits with the quality and comfort of stretch fabrics certified to perform with a new LYCRA® freshFX® technology brand standard. Preparation for this innovation is already underway, with an initial focus on Chinese local value chains for the Chinese consumer, and the introduction is earmarked for the Intertextile show in Shanghai at the end of August.
“Our goal at HeiQ is to enable brands and mills in the textile industry to bring more comfort, performance and sustainability to textile products while raising brand awareness with key consumers who will benefit the most from these innovations,” noted Carlo Centonze, co-founder and CEO of HeiQ Group. “This collaboration with The LYCRA Company not only brings the best minds together but also ensures our breakthrough innovations will be available for and benefit as many consumers as possible.”
“The collaboration is based on a strong foundation of common values and philosophies shared by our two companies,” said Julien Born, CEO at The LYCRA Company. “We look forward to exploring the natural synergies between us and uncovering new solutions for the apparel industry.”
The focus of these collaborations will be to address relevant consumer needs for quality, durability, and sustainable garments. Sample fabrics and garments will be available in late summer for commercial selection.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA ® , LYCRA HyFit ® , LYCRA ® T400 ® , COOLMAX ® , THERMOLITE® , ELASPAN® , SUPPLEX ® , and TACTEL ® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA ® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA ® freshFX ® is trademark of The LYCRA Company.
About HeiQ
Founded in 2005 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH) and listed on the London Stock Exchange Main Market (LSE:HEIQ), HeiQ is a leader in textile and materials innovation creating some of the most effective, durable and high-performance technologies on the market today. HeiQ strives to improve the lives of billions of people through pioneering textiles and materials innovation. Combining three areas of expertise – scientific research, specialty materials manufacturing and consumer ingredient branding – HeiQ is the ideal innovation partner to create differentiating and sustainable products and capture the added value at the point of sale. With its 14 offices, 7 manufacturing sites and 7 R&D hubs, HeiQ today employs 190 professionals. It has a total capacity of 45,000 tons of specialty chemicals per year and serves over 1,000 industrial customers in over 60 countries. Today, HeiQ’s consumer goods and medical devices can be found in 56 countries. For more information, visit www.heiq.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005642/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom